Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine if combination therapy (reduced-fluence Visudyne
followed by Lucentis [within 2 hours] or either of two regimens of reduced-fluence Visudyne
followed by Lucentis-Dexamethasone triple therapy [within 2 hours]) reduces retreatment rates
compared with Lucentis monotherapy while maintaining similar vision outcomes and an
acceptable safety profile.